Positive Medtech Revenues Into H2, But M&A And IPOs May Wait

Medtechs Count On Path To Greater Stability And Revenue Growth in H2 2022

 
• By Ashley Yeo

EY’s John Babitt provided a mid-year 2022 update on medtech investment trends, and the outlook for the industry going into 2023 in this commentary for In Vivo.

Shutterstock

John Babitt is a life sciences partner at EY, with 30 years of experience in the life sciences and health care industries. He advises strategic and private equity life science clients, and has a particular focus on medical technology.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Intelligence

More from In Vivo